Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-11-15 4:32 pm Sale | 13G | ARYA SCIENCES ACQUISITION CORP ARYD | RA CAPITAL MANAGEMENT L.P. | 0 0% | -1,000,000 (Position Closed) | View |
| 2021-11-15 4:31 pm Sale | 13G | ARDELYX INC ARDX | RA CAPITAL MANAGEMENT L.P. | 0 0% | -6,163,086 (Position Closed) | View |
| 2021-11-12 4:30 pm Purchase | 13D | WAVE LIFE SCIENCES LTD WVE | RA CAPITAL MANAGEMENT L.P. | 7,828,457 13.3% | 5,250 (+0.07%) | View |
| 2021-11-05 4:34 pm Purchase | 13G | XILIO THERAPEUTICS INC XLO | RA CAPITAL MANAGEMENT L.P. | 1,532,767 5.7% | 1,532,767 (New Position) | View |
| 2021-10-28 4:32 pm Purchase | 13D | FORMA THERAPEUTICS HLDGS INC FMTX | RA CAPITAL MANAGEMENT L.P. | 9,029,184 19.05% | 17,533 (+0.19%) | View |
| 2021-10-28 4:23 pm Purchase | 13D | KALA PHARMACEUTICALS INC KALA | RA CAPITAL MANAGEMENT L.P. | 10,961,533 16.85% | 86,920 (+0.80%) | View |
| 2021-10-25 4:35 pm Purchase | 13G | OTONOMY INC OTIC | RA CAPITAL MANAGEMENT L.P. | 3,092,294 5.5% | 3,092,294 (New Position) | View |
| 2021-10-25 4:34 pm Purchase | 13G | PYXIS ONCOLOGY INC PYXS | RA CAPITAL MANAGEMENT L.P. | 1,914,934 5.8% | 1,914,934 (New Position) | View |
| 2021-10-01 4:30 pm Purchase | 13G | SYNLOGIC INC SYBX | RA CAPITAL MANAGEMENT L.P. | 6,666,666 9.9% | 6,666,666 (New Position) | View |
| 2021-09-27 4:32 pm Purchase | 13D | DICE THERAPEUTICS INC DICE | RA CAPITAL MANAGEMENT L.P. | 5,208,911 14.3% | 5,208,911 (New Position) | View |
| 2021-09-27 4:30 pm Purchase | 13D | TYRA BIOSCIENCES INC TYRA | RA CAPITAL MANAGEMENT L.P. | 7,236,454 17% | 7,236,454 (New Position) | View |
| 2021-09-14 4:30 pm Unchanged | 13D | POINT BIOPHARMA GLOBAL INC PNT | RA CAPITAL MANAGEMENT L.P. | 8,856,018 9.8% | 0 (Unchanged) | View |
| 2021-09-13 4:30 pm Purchase | 13D | ACUMEN PHARMACEUTICALS INC ABOS | RA CAPITAL MANAGEMENT L.P. | 9,774,551 24.2% | 3,778 (+0.04%) | View |
| 2021-08-23 4:30 pm Purchase | 13G | AERPIO PHARMACEUTICALS INC ARPO | RA CAPITAL MANAGEMENT L.P. | 2,486,242 5.22% | 911,436 (+57.88%) | View |
| 2021-08-19 4:30 pm Purchase | 13D | ELIEM THERAPEUTICS INC ELYM | RA CAPITAL MANAGEMENT L.P. | 13,151,959 50% | 13,151,959 (New Position) | View |
| 2021-08-18 5:30 pm Purchase | 13D | WAVE LIFE SCIENCES LTD WVE | RA CAPITAL MANAGEMENT L.P. | 7,823,207 15.39% | 48,000 (+0.62%) | View |
| 2021-08-16 4:32 pm Sale | 13G | ADVERUM BIOTECHNOLOGIES INC CO ADVM | RA CAPITAL MANAGEMENT L.P. | 0 0% | -9,502,383 (Position Closed) | View |
| 2021-08-13 4:31 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | RA CAPITAL MANAGEMENT L.P. | 1,606,859 5.6% | 1,606,859 (New Position) | View |
| 2021-08-13 4:30 pm Purchase | 13G | RXSIGHT INC RXST | RA CAPITAL MANAGEMENT L.P. | 3,052,796 11.1% | 3,052,796 (New Position) | View |
| 2021-08-12 4:30 pm Purchase | 13D | ICOSAVAX INC ICVX | RA CAPITAL MANAGEMENT L.P. | 5,779,347 14.7% | 5,779,347 (New Position) | View |